Transient electromyographic findings in serotonergic toxicity due to combination of essitalopram and isoniazid

Address for correspondence: Prof. Çağdas Erdoğan Department of Neurology, Pamukkale University, School of Medicine Denizli Turkey drcagdaserdogan@gmail.com

Journal of Neurosciences in Rural Practice

Licence

This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Private Ltd. and was migrated to Scientific Scholar after the change of Publisher; therefore Scientific Scholar has no control over the quality or content of this article.

Abstract

ABSTRACT

Here, we report a case of serotonergic toxicity due to combination of essitalopram and isoniazid, which was rarely reported before. Moreover, we observed transient neurogenic denervation potentials in needle electromyography, which disappeared with the treatment of serotonergic toxicity. As to our best knowledge, this is the first case, reporting transient electromyographic changes probably due to serotonergic toxicity.

Keywords

Denervation potentials

electromyography

essitalopram

isoniazid

serotonergic toxicity

Show Related Articles from PubMed

Conflicts of interest

None declared

REFERENCES

Gillman P. K., . Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. J Clin Psychopharmacol. 2011;31:66-74.
[Google Scholar]
Polasek T. M., Elliot D. J., Somogyi A. A., Gillam E. M., Lewis B. C., Miners J. O., . An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol. 2006;61:570-84.
[Google Scholar]
Doyle M. E., Hicks D, Aronson N. E., . Selective serotonin reuptake inhibitors and isoniazid: Evidence of a potential adverse interaction. Mil Med. 2001;166:1054-6.
[Google Scholar]
Gillman P. K., . A review of serotonin toxicity data: Implications for the mechanisms ofantidepressant drug action. Biol Psychiatry. 2006;59:1046-51.
[Google Scholar]
Boyer E. W., Shannon M, . The serotonin syndrome. N Engl J Med. 2005;352:1112-20.
[Google Scholar]
Radomki J. W., Dursun S. M., Reveley M. A., Kutcher S. P., . An exploratory approach to the serotonin syndrome: An update of clinical phenomenology and revised diagnostic criteria. Med Hypotheses. 2000;53:218-24.
[Google Scholar]
Nemeroff C. B., Preskorn S. H., Devane C. L., . Antidepressant drug-drug interactions: Clinical relevance and risk management. CNS Spectr. 2007;12:1-13.
[Google Scholar]
Nelson L. S., Erdman A. R., Booze L. L., Cobaugh D. J., Chyka P. A., Woolf A. D., et al. . Selective serotonin reuptake inhibitor poisoning: An evidencebased consensus guideline for out-of-hospital management. Clin Toxicol. 2007;45:315-32.
[Google Scholar]
Huska M. T., Catalano G, Catalano M. C., . Serotonin syndrome associatedwith the use of escitalopram. CNS Spectr. 2007;12:270-4.
[Google Scholar]
Sternbach H, . Serotonin syndrome: How to avoid, identify, and treat dangerous drug interactions. Curr Psych. 2003;5:15-24.
[Google Scholar]

Fulltext Views
32

PDF downloads
2

View/Download PDF
Download Citations

BibTeX
RIS

Show Sections

[1] Gillman P. K., . Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. J Clin Psychopharmacol. 2011;31:66-74.
[Google Scholar]

[2] Polasek T. M., Elliot D. J., Somogyi A. A., Gillam E. M., Lewis B. C., Miners J. O., . An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol. 2006;61:570-84.
[Google Scholar]

[3] Doyle M. E., Hicks D, Aronson N. E., . Selective serotonin reuptake inhibitors and isoniazid: Evidence of a potential adverse interaction. Mil Med. 2001;166:1054-6.
[Google Scholar]

[4] Gillman P. K., . A review of serotonin toxicity data: Implications for the mechanisms ofantidepressant drug action. Biol Psychiatry. 2006;59:1046-51.
[Google Scholar]

[5] Boyer E. W., Shannon M, . The serotonin syndrome. N Engl J Med. 2005;352:1112-20.
[Google Scholar]

[6] Radomki J. W., Dursun S. M., Reveley M. A., Kutcher S. P., . An exploratory approach to the serotonin syndrome: An update of clinical phenomenology and revised diagnostic criteria. Med Hypotheses. 2000;53:218-24.
[Google Scholar]

[7] Nemeroff C. B., Preskorn S. H., Devane C. L., . Antidepressant drug-drug interactions: Clinical relevance and risk management. CNS Spectr. 2007;12:1-13.
[Google Scholar]

[8] Nelson L. S., Erdman A. R., Booze L. L., Cobaugh D. J., Chyka P. A., Woolf A. D., et al. . Selective serotonin reuptake inhibitor poisoning: An evidencebased consensus guideline for out-of-hospital management. Clin Toxicol. 2007;45:315-32.
[Google Scholar]

[9] Huska M. T., Catalano G, Catalano M. C., . Serotonin syndrome associatedwith the use of escitalopram. CNS Spectr. 2007;12:270-4.
[Google Scholar]

[10] Sternbach H, . Serotonin syndrome: How to avoid, identify, and treat dangerous drug interactions. Curr Psych. 2003;5:15-24.
[Google Scholar]